Antibody diversification: Mutational mechanisms and oncogenesis

Immunologic Research

Volumn 35, Issue 1-2, 2006, Pages 75-87

  Frieder, Darina ^a   Larijani, Mani ^a   Tang, Ephraim ^a   Parsa, Jahan Yar ^a   Basit, Wajiha ^a   Martin, Alberto ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Activation induced cytidine deaminase; Antibody; Class switch recombination; Gene conversion; Immunoglobulin; Somatic hypermutation

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ANTIBODY; CYTIDINE; CYTIDINE DEAMINASE; DNA; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; CANCER IMMUNOLOGY; CARCINOGENESIS; DNA DAMAGE; DNA REPAIR; GENE CONVERSION; GENE REARRANGEMENT; GENETIC RECOMBINATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN CONSTANT REGION; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOMA; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC HYPERMUTATION;

EID: 33749606999     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:35:1:75     Document Type: Review

References (116)

1. Revy P, Muto T, Levy Y, et al: Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 2000;102:565-575.
2. Martin A, Scharff MD: AID and mismatch repair in antibody diversification. Nature Rev Immunol 2002;2:605-614.
3. Thomas CM, Nielsen KM: Mechanisms of, and barriers to, horizontal gene transfer between bacteria. Nat Rev Microbiol 2005;3:711-721.
4. Lewis SM, Wu GE: The origins of V(D)J recombination. Cell 1997;88:159-162.
5. Gellert M: V(D)J recombination: RAG proteins, repair factors, and regulation. Annu Rev Biaochem 2002;71:101-132.
6. Arakawa H, Buerstedde JM: Immunoglobulin gene conversion: insights from bursal B cells and the DT40 cell line. Dev Dyn 2004;229:458-464.
7. Li Z, Woo CJ, Iglesias-Ussel MD, Ronai D, Scharff MD: The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev 2004;18:1-11.
8. Dudley DD, Chaudhuri J, Bassing CH, Alt FW: Mechanism and control of V(D)J recombination versus class switch recombination: similarities and differences. Adv Immunol 2005;86:43-112.
9. Fugmann SD, Lee AI, Shockett PE, Villey IJ, Schatz DG: The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annu Rev Immunol 2000;18:495-527.
10. Muramatsu M, Sankaranand VS, Anant S, et al: Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 1999;274:18470-18476.
11. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T: Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-563.
12. Arakawa H, Hauschild J, Buerstedde JM: Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion. Science 2002;295: 1301-1306.
13. Harris RS, Sale JE, Petersen-Mahrt SK, Neuberger MS: AID is essential for immunoglobulin V gene conversion in a cultured B cell line. Curr Biol 2002;12:435-438.
14. Muto T, Muramatsu M, Taniwaki M, Kinoshita K, Honjo T: Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene. Genomics 2000;68:85-88.
15. Martin A, Bardwell PD, Woo CJ, Fan M, Shulman MJ, Scharff MD: Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature 2002;415:802-806.
16. Yoshikawa K, Okazaki IM, Eto T, et al: AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science 2002;296:2033-2036.
17. Okazaki IM, Kinoshita K, Muramatsu M, Yoshikawa K, Honjo T: The AID enzyme induces class switch recombination in fibroblasts. Nature 2002;416:340-345.
18. Martin A, Scharff MD: Somatic hypermutation of the AID transgene in B and non-B cells. Proc Natl Acad Sci USA 2002;99:12304-12308.
19. Di Noia J, Neuberger MS: Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 2002;419:43-48.
20. Poltoratsky VP, Wilson SH, Kunkel TA, Pavlov YI: Recombinogenic phenotype of human activation-induced cytosine deaminase. J Immunol 2004;172:4308-4313.
21. Krause K, Marcu KB, Greeve J: The cytidine deaminases AID and APOBEC-1 exhibit distinct functional properties in a novel yeast selectable system. Mol Immunol 2006;43:295-307.
22. Rogozin IB, Pavlov YI: The cytidine deaminase AID exhibits similar functional properties in yeast and mammals. Mol Immunol 2006;43:1481-1484.
23. Rada C, Williams GT, Nilsen H, Barnes DE, Lindahl T, Neuberger MS: Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. Curr Biol 2002;12:1748-1755.
24. Pham P, Bransteitter R, Petruska J, Goodman MF: Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 2003;424:103-107.
25. Bransteitter R, Pham P, Scharff MD, Goodman MF: Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci USA 2003;100: 4102-4107.
26. Larijani M, Frieder D, Basit W, Martin A: The mutation spectrum of purified AID is similar to the mutability index in Ramos cells and in ung-/-msh2-/- mice. Immunogenetics 2005;56:840-845.
27. Larijani M, Frieder D, Sonbuchner TM, Bransteitter R, Goodman MF, Bouhassira EE, et al: Methylation protects cytidines from AID-mediated deamination. Mol Immunol 2005;42:599-604.
28. Sohail A, Klapacz J, Samaranayake M, Ullah A, Bhagwat AS: Human activation-induced cytidine deaminase causes transcription-dependent, strand-biased C to U deaminations. Nucleic Acids Res 2003;31:2990-2994.
29. Honjo T, Muramatsu M, Fagarasan S: AID: how does it aid antibody diversity? Immunity 2004;20:659-668.
30. Peters A, Storb U: Somatic hypermutation of immunoglobulin genes is linked to transcription initiation. Immunity 1996;4:57-65.
31. Shen HM, Michael N, Kim N, Storb U: The TATA binding protein, c-Myc and survivin genes are not somatically hypermutated, while Ig and BCL6 genes are hypermutated in human memory B cells. Int Immunol 2000;12:1085-1093.
32. Ramiro AR, Stavropoulos P, Jankovic M, Nussenzweig MC: Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. Nat Immunol 2003;14:14.
33. Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW: Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 2003;422:726-730.
34. Wu X, Geraldes P, Platt JL, Cascalho M: The double-edged sword of activation-induced cytidine deaminase. J Immunol 2005;174:934-941.
35. Chaudhuri J, Khuong C, Alt FW: Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. Nature 2004;430:992-998.
36. Basu U, Chaudhuri J, Alpert C, et al: The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. Nature 2005;438:508-511.
37. Barreto V, Reina-San-Martin B, Ramiro AR, McBride KM, Nussenzweig MC: C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol Cell 2003; 12:501-508.
38. Shinkura R, Ito S, Begum NA, et al: Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat Immunol 2004;5:707-712.
39. Reynaud CA, Anquez V, Grimal H, Weill JC: A hyperconversion mechanism generates the chicken light chain preimmune repertoire. Cell 1987;48:379-388.
40. Sayegh CE, Demaries SL, Pike KA, Friedman JE, Ratcliffe MJ: The chicken B-cell receptor complex and its role in avian B-cell development. Immunol Rev 2000;175:187-200.
41. Sale JE, Calandrini DM, Takata M, Takeda S, Neuberger MS: Ablation of XRCC2/3 transforms immunoglobulin V gene conversion into somatic hypermutation. Nature 2001;412:921-926.
42. Bezzubova O, Silbergleit A, Yamaguchi-Iwai Y, Takeda S, Buerstedde JM: Reduced X-ray resistance and homologous recombination frequencies in a RAD54-/-mutant of the chicken DT40 cell line. Cell 1997;89:185-193.
43. McCormack WT, Thompson CB: Chicken IgL variable region gene conversions display pseudogene donor preference and 5′ to 3′ polarity. Genes Dev 1990;4:548-558.
44. Krokan HE, Drablos F, Slupphaug G: Uracil in DNA-occurrence, consequences and repair. Oncogene 2002;21:8935-8948.
45. Yabuki M, Fujii MM, Maizels N: The MRE11-RAD50-NBS1 complex accelerates somatic hypermutation and gene conversion of immunoglobulin variable regions. Nat Immunol 2005;6:730-736.
46. Chaudhuri J, Alt FW: Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat Rev Immunol 2004;4:541-552.
47. Pinaud E, Khamlichi AA, Le Morvan C, et al: Localization of the 3′ IgH locus elements that effect long-distance regulation of class switch recombination. Immunity 2001;15:187-199.
48. Duquette ML, Handa P, Vincent JA, Taylor AF, Maizels N: Intracellular transcription of G-rich DNAs induces formation of G-loops, novel structures containing G4 DNA. Genes Dev 2004;18:1618-1629.
49. Yu K, Chedin F, Hsieh CL, Wilson TE, Lieber MR: R-loops at immunoglobulin class switch regions in the chromosomes of stimulated B cells. Nat Immunol 2003;4:442-451.
50. Rada C, Di Noia JM, Neuberger MS: Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. Mol Cell 2004;16:163-171.
51. Reina-San-Martin B, Nussenzweig MC, Nussenzweig A, Difilippantonio S: Genomic instability, endoreduplication, and diminished Ig class-switch recombination in B cells lacking Nbs1. Proc Natl Acad Sci USA 2005;102:1590-1595.
52. Manis JP, Gu Y, Lansford R, et al: Ku70 is required for late B cell development and immunoglobulin heavy chain class switching. J Exp Med 1998;187:2081-2089.
53. Lumsden JM, McCarty T, Petiniot LK, et al: Immunoglobulin class switch recombination is impaired in Atm-deficient mice. J Exp Med 2004;200:1111-1121.
54. Reina-San-Martin B, Chen HT, Nussenzweig A, Nussenzweig MC: ATM is required for efficient recombination between immunoglobulin switch regions. J Exp Med 2004;200:1103-1110.
55. Reina-San-Martin B, Difilippantonio S, Hanitsch L, Masilamani RF, Nussenzweig A, Nussenzweig MC: H2AX is required for recombination between immunoglobulin switch regions but not for intra-switch region recombination or somatic hypermutation. J Exp Med 2003;197:1767-1778.
56. Martomo SA, Fu D, Yang WW, Joshi NS, Gearhart PJ: Deoxyuridine is generated preferentially in the non-transcribed strand of DNA from cells expressing activation-induced cytidine deaminase. J Immunol 2005; 174:7787-7791.
57. Schrader CE, Linehan EK, Mochegova SN, Woodland RT, Stavnezer J: Inducible DNA breaks in Ig S regions are dependent on AID and UNG. J Exp Med 2005; 202:561-568.
58. Rada C, Ehrenstein MR, Neuberger MS, Milstein C: Hot spot focusing of somatic hypermutation in MSH2-deficient mice suggests two stages of mutational targeting. Immunity 1998;9:135-141.
59. Phung QH, Winter DB, Cranston A, et al: Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. J Exp Med 1998;187:1745-1751.
60. Wiesendanger M, Kneitz B, Edelmann W, Scharff MD: Somatic hypermutation in MutS homologue (MSH)3-, MSH6-, and MSH3/MSH6-deficient mice reveals a role for the MSH2-MSH6 heterodimer in modulating the base substitution pattern. J Exp Med 2000;191: 579-584.
61. Bertocci B, Quint L, Delbos F, Garcia C, Reynaud CA, Weill JC: Probing immunoglobulin gene hypermutation with microsatellites suggests a nonreplicative short patch DNA synthesis process. Immunity 1998;9:257-265.
62. Martin A, Li Z, Lin DP, et al: Msh2 ATPase activity is essential for somatic hypermutation at A-T basepairs and for efficient class switch recombination. J Exp Med 2003;198:1171-1178.
63. Peltomaki P, Vasen HF: Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997;113:1146-1158.
64. Wei K, Kucherlapati R, Edelmann W: Mouse models of human DNA mismatch repair gene defects. Trends Mol Med 2002;8:346-353.
65. Bardwell PD, Woo CJ, Wei K, et al: Altered somatic hypermutation and reduced class-switch recombination in exonuclease 1-mutant mice. Nat Immunol 2004;5:224-229.
66. Zan H, Komori A, Li Z, et al: The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation. Immunity 2001;14:643-653.
67. Diaz M, Verkoczy LK, Flajnik MF, Klinman NR: Decreased frequency of somatic hypermutation and impaired affinity maturation but intact germinal center formation in mice expressing antisense RNA to DNA polymerase zeta. J Immunol 2001;167:327-335.
68. Zeng X, Winter DB, Kasmer C, Kraemer KH, Lehmann AR, Gearhart PJ: DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. Nat Immunol 2001;2:537-541.
69. Poltoratsky V, Woo CJ, Tippin B, Martin A, Goodman MF, Scharff MD: Expression of error-prone polymerases in BL2 cells activated for Ig somatic hypermutation. Proc Natl Acad Sci USA 2001;98:7976-7981.
70. Faili A, Aoufouchi S, Flatter E, Gueranger Q, Reynaud CA, Weill JC: Induction of somatic hypermutation in immunoglobulin genes is dependent on DNA polymerase iota. Nature 2002;419:944-947.
71. Zan H, Shima N, Xu Z, et al: The translesion DNA polymerase theta plays a dominant role in immunoglobulin gene somatic hypermutation. EMBO J 2005;24:3757-3769.
72. Pavlov YI, Rogozin IB, Galkin AP, et al: Correlation of somatic hypermutation specificity and A-T base pair substitution errors by DNA polymerase eta during copying of a mouse immunoglobulin kappa light chain transgene. Proc Natl Acad Sci USA 2002;99: 9954-9959.
73. Faili A, Aoufouchi S, Weller S, et al: DNA polymerase eta is involved in hypermutation occurring during immunoglobulin class switch recombination. J Exp Med 2004;199:265-270.
74. Li Z, Scherer SJ, Ronai D, et al: Examination of Msh6- and Msh3-deficient mice in class switching reveals overlapping and distinct roles of MutS homologues in antibody diversification. J Exp Med 2004; 200:47-59.
75. Cascalho M, Wong J, Steinberg C, Wabl M: Mismatch repair co-opted by hypermutation. Science 1998; 279:1207-1210.
76. Phung QH, Winter DB, Alrefai R, Gearhart PJ: Hypermutation in Ig V genes from mice deficient in the MLH1 mismatch repair protein. J Immunol 1999;162: 3121-3124.
77. Ehrenstein MR, Neuberger MS: Deficiency in msh2 affects the efficiency and local sequence specificity of immunoglobulin class-switch recombination: parallels with somatic hypermutation. EMBO J 1999;18: 3484-3490.
78. Schrader CE, Edelmann W, Kucherlapati R, Stavnezer J: Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes. J Exp Med 1999;190:323-330.
79. Ehrenstein MR, Rada C, Jones AM, Milstein C, Neuberger MS: Switch junction sequences in PMS2-deficient mice reveal a microhomology-mediated mechanism of Ig class switch recombination. Proc Natl Acad Sci USA 2001;98:14553-14558.
80. Schrader CE, Vardo J, Stavnezer J: Role for mismatch repair proteins Msh2, Mlh1, and Pms2 in immunoglobulin class switching shown by sequence analysis of recombination junctions. J Exp Med 2002;195: 367-373.
81. Larijani M, Zaheen A, Frieder D, et al: Lack of MSH2 involvement differentiates V(D)J recombination from other non-homologous end joining events. Nucleic Acids Res 2005;33:6733-6742.
82. Pasqualucci L, Migliazza A, Fracchiolla N, et al: BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci USA 1998;95:11816-11821.
83. Shen HM, Peters A, Baron B, Zhu X, Storb U: Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998;280:1750-1752.
84. Muschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Kuppers R: Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med 2000;192:1833-1840.
85. Gordon MS, Kanegai CM, Doerr JR, Wall R: Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a). Proc Natl Acad Sci USA 2003;100:4126-4131.
86. Pasqualucci L, Neumeister P, Goossens T, et al: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-346.
87. Bachl J, Carlson C, Gray-Schopfer V, Dessing M, Olsson C: Increased transcription levels induce higher mutation rates in a hypermutating cell line. J Immunol 2001;166:5051-5057.
88. Woo CJ, Martin A, Scharff MD: Induction of somatic hypermutation is associated with modifications in immunoglobulin variable region chromatin. Immunity 2003;19:479-489.
89. Li Z, Luo Z, Scharff MD: Differential regulation of histone acetylation and generation of mutations in switch regions is associated with Ig class switching. Proc Natl Acad Sci USA 2004;101:15428-15433.
90. Michael N, Shen HM, Longerich S, Kim N, Longacre A, Storb U: The E box motif CAGGTG enhances somatic hypermutation without enhancing transcription. Immunity 2003;19:235-242.
91. Yu K, Huang FT, Lieber MR: DNA substrate length and surrounding sequence affect the activation-induced deaminase activity at cytidine. J Biol Chem 2004;279: 6496-6500.
92. Betz AG, Milstein C, Gonzalez-Fernandez A, Pannell R, Larson T, Neuberger MS: Elements regulating somatic hypermutation of an immunoglobulin kappa gene: critical role for the intron enhancer/matrix attachment region. Cell 1994;77:239-248.
93. Goyenechea B, Klix N, Yelamos J, et al: Cells strongly expressing Ig(kappa) transgenes show clonal recruitment of hypermutation: a role for both MAR and the enhancers. EMBO J 1997;16:3987-3994.
94. Klix N, Jolly CJ, Davies SL, Bruggerman M, Williams GT, Neuberger M: Multiple sequences from downstream of the Jk cluster can combine to recruit somatic hypermutation to a heterologous, upstream mutation domain. Eur J Immunol 1998;28:317-326.
95. Yelamos J, Klix N, Goyenechea B, et al: Targeting of non-Ig sequences in place of the V segment by somatic hypermutation. Nature 1995;376:225-229.
96. Kodama M, Hayashi R, Nishizumi H, Nagawa F, Takemori T, Sakano H: The PU.1 and NF-EM5 binding motifs in the Igkappa 3′ enhancer are responsible for directing somatic hypermutations to the intrinsic hotspots in the transgenic Vkappa gene. Int Immunol 2001;13:1415-1422.
97. Lin MM, Zhu M, Scharff MD: Sequence dependent hypermutation of the immunoglobulin heavy chain in cultured B cells. Proc Natl Acad Sci USA 1997;94: 5284-5289.
98. Lin MM, Green NS, Zhang W, Scharff MD: The effects of Eμ, 3′α (hs, 1,2) and 3′κ enhancers on mutation of an lg-VDJ-Cγ2a immunoglobulin heavy gene in cultured B cells. Internat Immunol 1998;10:1121-1129.
99. Wang CL, Harper RA, Wabl M: Genome-wide somatic hypermutation. Proc Natl Acad Sci USA 2004;101: 7352-7356.
100. Bachl J, Olsson C, Chitkara N, Wabl M: The Ig mutator is dependent on the presence, position, and orientation of the large intron enhancer. Proc Natl Acad Sci USA 1998;95:2396-2399.
101. Tumas-Brundage K, Manser T: The transcriptional promoter regulates hypermutation of the antibody heavy chain locus. J Exp Med 1997;185:239-250.
102. Fukita Y, Jacobs H, Rajewsky K: Somatic hypermutation in the heavy chain locus correlates with transcription. Immunity 1998;9:105-114.
103. Shen HM, Peters A, Kao D, Storb U: The 3′ Igkappa enhancer contains RNA polymerase II promoters: implications for endogenous and transgenic kappa gene expression. Int Immunol 2001;13:665-674.
104. Bachl J, Wabl M: Enhancers of hypermutation. Immunogenetics 1996;45:59-64.
105. Sale JE, Neuberger MS: TdT-accessible breaks are scattered over the immunoglobulin V domain in a constitutively hypermutating B cell line. Immunity 1998;9:859-869.
106. Zhang W, Bardwell PD, Woo CJ, Poltoratsky V, Scharff MD, Martin A: Clonal instability of V region hypermutation in the Ramos Burkitt's lymphoma cell line. Int Immunol 2001;13:1175-1184.
107. McCarthy H, Wierda WG, Barron LL, et al: High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood 2003;101:4903-4908.
108. Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM: Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 1985;315: 340-343.
109. Pasqualucci L, Neri A, Baldini L, Dalla-Favera R, Migliazza A: BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia. Cancer Res 2000;60:5644-5648.
110. Okazaki IM, Hiai H, Kakazu N, et al: Constitutive expression of AID leads to tumorigenesis. J Exp Med 2003;197:1173-1181.
111. Wang X, Li Z, Naganuma A, Ye BH: Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2002;99:15018-15023.
112. Offit K, Louie DC, Parsa NZ, et al: BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. Leuk Lymphoma 1995;20:85-89.
113. Taub R, Kirsch I, Morton C, et al: Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 1982;79: 7837-7841.
114. Ye BH, Rao PH, Chaganti RS, Dalla-Favera R: Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res 1993;53:2732-2735.
115. Ramiro AR, Jankovic M, Eisenreich T, et al: AID is required for c-myc/IgH chromosome translocations in vivo. Cell 2004;118:431-438.
116. Unniraman S, Zhou S, Schatz DG: Identification of an AID-independent pathway for chromosomal translocations between the Igh switch region and Myc. Nat Immunol 2004;5:1117-1123.